Clinical Trials

The James Cancer Center Columbus, OH

open for enrollment

CAPTIVE: Combination Adenovirus + Pembrolizumab to Trigger Immune Virus Effects

Protocol: OSU-16034

Full Title

A Phase II, Multi-center, Open-label Study of a Conditionally Replicative Adenovirus (DNX-2401) with Pembrolizumab (KEYTRUDA®) for Recurrent Glioblastoma or Gliosarcoma

Other Brain Cancers Brain Cancer Gliomas